Janssen continues to prioritize hepatitis B research, with the aim to bring forward an optimal combination treatment regimen
Collaborations between Janssen and Bavarian Nordic in HIV and Ebola continue
NEW BRUNSWICK, NJ, May 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the termination of its collaboration and license agreements with Bavarian Nordic that leverage Bavarian Nordic’s MVA-BN® (Modified Vaccinia Ankara – Bavarian Nordic) technology to develop potential vaccines against the hepatitis B virus and human papillomaviruses. Janssen remains committed to its strong collaboration with Bavarian Nordic in the quest to prevent and cure infectious diseases – with collaborations in HIV and Ebola still ongoing.
No clinical studies in hepatitis B have been initiated by Janssen utilizing the MVA-BN® technology.
Janssen will continue to prioritize investigation of its hepatitis B combination therapies using alternative investigational vaccine platforms and therapeutics within its broad portfolio and has multiple studies ongoing. Hepatitis B remains a critical global health issue, affecting an estimated 296 million people worldwide, and claiming nearly 900,000 lives every year.[1] Through its diverse scientific approach, Janssen is determined in its pursuit of a functional cure* for chronic hepatitis B to improve health outcomes for those living with the disease.
There has been widespread uptake of effective, preventive vaccines against human papillomaviruses.[2] Due to this and the prioritization of other programs, Janssen will not be focusing R&D efforts on a therapeutic vaccine against human papillomaviruses at this time.
Janssen is committed to the research and development of transformational vaccines and therapeutics to prevent and cure infectious diseases with high unmet need. Janssen’s infectious diseases and vaccines projects span all stages of development, from discovery through late development, addressing major global health threats including COVID-19, HIV, RSV, influenza, multi-drug resistant bacterial infections and Ebola.
For more information on Janssen’s commitment to battling infectious diseases, visit www.janssen.com/infectious-diseases-and-vaccines/IDV-News/.
*A functional cure for chronic hepatitis B is defined as a loss of viral markers (hepatitis B surface antigen [HBsAg] and hepatitis B viral DNA) that is sustained after cessation of treatment.
###
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal.
Janssen Pharmaceuticals Inc. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
###
[1] World Health Organization (WHO). Hepatitis B. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Last accessed: April 2022.[2] Centers for Disease Control and Prevention (CDC). Human Papillomavirus (HPV) Vaccine Safety and Effectiveness. Available at: https://www.cdc.gov/vaccines/vpd/hpv/hcp/safety-effectiveness.html#hpvvxeff. Last accessed: April 2022.
Source : Johnson & Johnson
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.